Protocols: Troubled Telesta axes staff in wake of FDA rejection; Evelo partners with Mayo researchers
Less than a year after striking a $137 million deal for the rights to Telesta’s bladder cancer drug MCNA, Ipsen has decided to punt the therapy, forcing deep cuts at the Montreal-based biotech. Telesta says that it is shrinking its work force to 15, down from 50 at the end of March. It’s also selling off its manufacturing facilities. The FDA rejected MCNA back in February, saying the biotech would need to do a new Phase III before it could get an approval. Telesta, though, says it won’t spend any new funds on the program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.